Michigan-focused academic drug discovery, development symposium presented by MichBio and the University Research Corridor

ANN ARBOR, Mich.--()--Michigan’s first event to showcase the state’s academic drug R&D activities will be held on September 9-10, 2015 and hosted by Michigan State University.

The “Cutting Edge / Drug Discovery & Development in Michigan Symposium” will discuss the development, funding, partnering, and commercialization of new academic therapeutic discoveries. It will bring together representatives from academia, industry, contract research organizations (CROs), funders, and others to talk about Michigan’s current drug discovery efforts and future capacity within the academic paradigm.

“There has been a largely unrecognized blossoming of drug discovery and development activity in the state, and the three major research universities – Michigan State University, the University of Michigan, and Wayne State University – have all invested heavily in this area,” explains Richard R. Neubig, MD, PhD, chair of Michigan State’s Department of Pharmacology and Toxicology. “This activity builds on the strong brain-trust of former pharma scientists and a substantial ecosystem of biotech and CRO firms in the state. We are excited to have an opportunity to present these relatively recent developments.”

Keynote speakers include Barbara Slusher, PhD of the Academic Drug Discovery Consortium and Johns Hopkins Medicine and Roger Newton, PhD of Esperion Therapeutics. The one-and-a-half day symposium’s agenda also includes session presentations, panel discussions, exhibit opportunities, poster presentations, and a cocktail reception.

Session presentation topics include:

  • Treatments for orphan diseases
  • Developing new anti-infective therapies
  • Clinical development – reaching the patient
  • From academic lab to commercialization – a founder’s tale

Panel discussion topics include:

  • The challenge of medicinal chemistry in academic and early stage drug development
  • Moving beyond the bench – pre-clinical selection
  • Building successful drug discovery partnerships with industry
  • Funding academic and early-stage drug discovery

Exhibit table registration and poster abstracts must be submitted by August 21, 2015.

Different registration rates are available for MichBio members, non-members, and academics (a student rate is also available). More event details, sponsorship information, and a link to register can be found at www.michbio.org/mi-drug-discovery.

This event is presented by the University Research Corridor and MichBio. NSF International is bronze level supporting sponsor.

Michigan’s University Research Corridor (URC) is one of the nation’s top academic research clusters and the leading engine for innovation in Michigan and the Great Lakes region. An alliance of Michigan State University, the University of Michigan, and Wayne State University, the URC is focused on increasing economic prosperity and connecting Michigan to the world. Visit www.urcmich.org or Twitter @urcmich for more information.

MichBio is the trade association committed to driving the growth of Michigan's biosciences industry and its many sectors by providing essential business services, resources and connections, information and news, promotion, and advocacy. MichBio members include bioscience companies, academic and clinical research institutions, bioscience service providers, and related organizations. For more information, visit www.michbio.org or follow us on Twitter @MichBio.

Contacts

MichBio
Katie Trevathan
Director, Marketing and Communications
734.527.9147 | katie@michbio.org

Contacts

MichBio
Katie Trevathan
Director, Marketing and Communications
734.527.9147 | katie@michbio.org